GLORIA

GEOMAR Library Ocean Research Information Access

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    In: The Journal of Clinical Endocrinology & Metabolism, The Endocrine Society, Vol. 105, No. 12 ( 2020-12-01), p. e4393-e4406
    Kurzfassung: We set forth to compare ethnicities for metabolic and immunological characteristics at the clinical diagnosis of type 1 diabetes (T1D) and assess the effect of ethnicity on beta-cell functional loss within 3 years after clinical diagnosis. Research Methods and Design We studied participants in TrialNet New Onset Intervention Trials (n = 624, median age = 14.4 years, 58% male, 8.7% Hispanic) and followed them prospectively for 3 years. Mixed meal tolerance tests (MMTT) were performed within 6 months following clinical diagnosis and repeated semiannually. Unless otherwise indicated, analyses were adjusted for age, sex, BMI Z-score, and diabetes duration. Results At T1D clinical diagnosis, Hispanics, compared with non-Hispanic whites (NHW), had a higher frequency of diabetic ketoacidosis (DKA) (44.7% vs 25.3%, OR = 2.36, P = 0.01), lower fasting glucose (97 vs 109 mg/dL, P = 0.02) and higher fasting C-peptide (1.23 vs 0.94 ng/mL, P = 0.02) on the first MMTT, and higher frequency of ZnT8 autoantibody positivity (n = 201, 94.1% vs 64%, OR = 7.98, P = 0.05). After exclusion of participants in experimental arms of positive clinical trials, C-peptide area under the curve (AUC) trajectories during the first 3 years after clinical diagnosis were not significantly different between Hispanics and NHW after adjusting for age, sex, BMI-z score, and DKA (n = 413, P = 0.14). Conclusion Despite differences in the metabolic and immunological characteristics at clinical diagnosis of T1D between Hispanics and NHW, C-peptide trajectories did not differ significantly in the first 3 years following clinical diagnosis after adjustment for body mass index and other confounders. These findings may inform the design of observational studies and intervention trials in T1D.
    Materialart: Online-Ressource
    ISSN: 0021-972X , 1945-7197
    RVK:
    Sprache: Englisch
    Verlag: The Endocrine Society
    Publikationsdatum: 2020
    ZDB Id: 2026217-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    In: The Journal of Clinical Endocrinology & Metabolism, The Endocrine Society, Vol. 100, No. 3 ( 2015-03-01), p. E463-E468
    Materialart: Online-Ressource
    ISSN: 0021-972X , 1945-7197
    RVK:
    Sprache: Englisch
    Verlag: The Endocrine Society
    Publikationsdatum: 2015
    ZDB Id: 2026217-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    In: The Journal of Clinical Endocrinology & Metabolism, The Endocrine Society, Vol. 102, No. 8 ( 2017-08-01), p. 2873-2880
    Kurzfassung: Genome-wide association studies identified & gt;50 type 1 diabetes (T1D) associated non-human leukocyte antigens (non-HLA) loci. Objective The purpose of this study was to assess the contribution of non-HLA single nucleotide polymorphisms (SNPs) to risk of disease progression. Design and Setting The TrialNet Pathway to Prevention Study follows relatives of T1D patients for development of autoantibodies (Abs) and T1D. Participants Using the Immunochip, we analyzed 53 diabetes-associated, non-HLA SNPs in 1016 Ab-positive, at-risk non-Hispanic white relatives. Main Outcome Measure Effect of SNPs on the development of multiple Abs and T1D. Results Cox proportional analyses included all substantial non-HLA SNPs, HLA genotypes, relationship to proband, sex, age at initial screening, initial Ab type, and number. Factors involved in progression from single to multiple Abs included age at screening, relationship to proband, HLA genotypes, and rs3087243 (cytotoxic T lymphocyte antigen-4). Significant factors for diabetes progression included age at screening, Ab number, HLA genotypes, rs6476839 [GLIS family zinc finger 3 (GLIS3)], and rs3184504 [SH2B adaptor protein 3 (SH2B3)] . When glucose area under the curve (AUC) was included, factors involved in disease progression included glucose AUC, age at screening, Ab number, relationship to proband, HLA genotypes, rs6476839 (GLIS3), and rs7221109 (CCR7). In stratified analyses by age, glucose AUC, age at screening, sibling, HLA genotypes, rs6476839 (GLIS3), and rs4900384 (C14orf64) were significantly associated with progression to diabetes in participants & lt;12 years old, whereas glucose AUC, sibling, rs3184504 (SH2B3), and rs4900384 (C14orf64) were significant in those ≥12. Conclusions In conclusion, we identified five non-HLA SNPs associated with increased risk of progression from Ab positivity to disease that may improve risk stratification for prevention trials.
    Materialart: Online-Ressource
    ISSN: 0021-972X , 1945-7197
    RVK:
    Sprache: Englisch
    Verlag: The Endocrine Society
    Publikationsdatum: 2017
    ZDB Id: 2026217-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    Online-Ressource
    Online-Ressource
    American Association for Cancer Research (AACR) ; 2012
    In:  Cancer Research Vol. 72, No. 8_Supplement ( 2012-04-15), p. 2249-2249
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 2249-2249
    Kurzfassung: Hepatocellular carcinoma (HCC) is currently the third most common cause of cancer related mortality worldwide. As with many cancers, aberrant activation of Wnt/β-catenin signaling plays a critical pathogenic role in the disease. Somatic mutations in genes of the Wnt pathway are widely observed in tumor tissue, where it has been estimated that 15-20% of tumors possess activating mutations in beta-catenin (CTNNB1). The turnover of CTNNB1 protein is tightly regulated in cells by the degradation complex which includes the CK1α and GSK3β kinases in a complex with Axin and APC. Mutations within the CTNNB1 gene at the CK1α phosphorylation site (Ser45) and GSK3β phosphorylation sites (Ser33, Ser37, Thr41) are observed clinically and result in CTNNB1 protein accumulation and enhanced transcription of Wnt target genes. The goal of this study is to characterize additional clinically observed CTNNB1 mutations in HCC. It is hypothesized that mutations within the phosphorylation domain in exon 3 will impact the phosphorylation of these key regulatory sites of CTNNB1. To assess the impact of three observed CTNNB1 mutations (H36P, I35S and S23R) on Wnt signaling activity, mutant CTNNB1 constructs were first created and their impact on Wnt signaling was measured using a luciferase-based Wnt reporter assay in transfected HEK293T cells. Compared to the wild type CTNNB1 control, Wnt transcription activity in the presence of H36P, I35S, and S23R mutants were increased by 6.55 ± 2.08, 6.76 ± 2.44, and 2.36 ± 1.01 fold, respectively. This compared to a 5.91 ± 1.38 fold increase observed with the phosphorylation mutant S45P. To evaluate if these mutations had a measurable impact on GSK3β regulation of CTNNB1 levels, each mutant was coexpressed with a GSK3β expression vector and evaluated using the same Wnt reporter system. As anticipated, GSK3β coexpression reduced Wnt reporter activity of the CTNNB1 control by 3.6 fold ± .33 where the S45P mutant was not affected. Coexpression of GSK3β did not attenuate increased Wnt activity observed with the mutants H36P and I35S, however it did decrease activity observed with the S23R by a similar magnitude of the wild type CTNNB1 control (2.27 fold ± .93). These results describe the activating nature of H36P, S45P, and I35S which likely mediate their effect via impaired CTNNB1 phosphorylation. To a lesser extent, S23R activated Wnt activity, however, is subject to attenuation by GSK3β phosphorylation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2249. doi:1538-7445.AM2012-2249
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2012
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...